SNBIF (SanBio Co) Ending Cash Position: $0.00 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNBIF SanBio Co Ltd SNBIF
23 GF Score
Price $16.45
! 1 Warning Sign
View Full Analysis

What is SanBio Co Ending Cash Position?

SanBio Co SNBIF 23 Ending Cash Position is $0.00 Mil as of Jan. 2026. GuruFocus rates SNBIF with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

SanBio Co's Ending Cash Position for the quarter that ended in Jan. 2026 was $0.00 Mil.

SanBio Co's annual Ending Cash Position declined from Jan. 2024 ($30.01 Mil) to Jan. 2025 ($18.23 Mil) but then increased from Jan. 2025 ($18.23 Mil) to Jan. 2026 ($94.58 Mil).

SanBio Co Ending Cash Position Related Terms

SanBio Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SanBio Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co Ending Cash Position Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.69 51.17 30.01 18.23 94.58

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNBIF
23GF Score
SanBio Co Ltd SNBIF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SanBio Co's Ending Cash Position for the fiscal year that ended in Jan. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.213+76.362
=94.58

SanBio Co's Ending Cash Position for the quarter that ended in Jan. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
SanBio Co (SNBIF) has a Ending Cash Position of $0.00 Mil as of Jan. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SanBio Co and its competitors.
Is SanBio Co's Ending Cash Position too high?
SanBio Co's current Ending Cash Position is $0.00 Mil. Overall, SanBio Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Ending Cash Position compare to VRTX and REGN?
SanBio Co's Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SanBio Co and its competitors. SanBio Co's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current Ending Cash Position of $0.00 Mil. The current Ending Cash Position is $0.00 Mil. SanBio Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SanBio Co (SNBIF), the current Ending Cash Position is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Other Exchanges 4592:Japan
Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
23GF Score

Get the complete analysis for SNBIF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.45
Price